13F Holdings
中文EN

PTPI Petros Pharmaceuticals, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1815903 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-12.2%
TTM net income YoY-75.4%
TTM EPS YoY-1,214.5%
Revenue 3-yr CAGR-13.2%
Net income 3-yr CAGR—

Margins

Gross margin76.3%
Operating margin-90.5%
Net margin-280.1%
FCF margin—
EBITDA margin-35.1%

Returns

ROE-622.1%
ROA-64.5%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets170.2%
Debt / equity—
Current ratio0.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio-52.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$5.11M$5.82M$5.99M$7.81M
Cost of revenue—$1.21M$1.63M$2.29M$1.60M
Gross profit—$3.90M$4.19M$3.70M$6.21M
R&D expense—$2.62M$2.41M$1.74M$1.79M
SG&A expense$4.64M$4.63M$9.26M$12.21M$15.59M
Operating income-$4.64M-$4.63M-$13.62M-$19.92M-$18.05M
Interest expense—$560,909$536,138$596,018$368,660
Pretax income-$4.50M-$705,174-$8.16M-$20.04M-$8.99M
Income tax$0$0$0—$0
Net income$1.91M-$14.32M-$8.16M-$20.04M-$8.99M
EBITDA—-$1.80M-$10.33M-$14.32M-$11.17M
EPS (basic)-1.56-83.47-6.35-9.68-8.25
EPS (diluted)-1.56-83.47-6.35-9.68-8.25
Weighted avg. shares (diluted)28.07M321,0422.18M2.07M1.09M
Banking
Net interest income$256,933$371,769$515,311$14,194—
Balance sheet
Cash & equivalents$5.14M$1.72M$13.34M$9.43M$23.85M
Receivables—$416,076$2.23M$2.11M$2.46M
Inventory—$1.35M$1.61M$1.82M$519,649
Current assets$5.16M$7.29M$20.39M$14.67M$30.54M
PP&E, net—$22,948$28,957$39,177$49,397
Intangibles—$3.20M$8.97M$12.24M$25.29M
Total assets$5.16M$10.64M$33.80M$32.42M$67.39M
Current liabilities$2.29M$18.03M$10.77M$7.07M$30.98M
Total liabilities$2.29M$18.10M$21.32M$15.72M$31.85M
Shareholders' equity$2.87M-$7.47M$12.07M$16.70M$35.54M
Shares outstanding42.28M421,1242.99M2.08M2.07M
Cash flow statement
Operating cash flow-$6.73M-$2.60M-$7.63M-$12.80M-$11.86M
Capital expenditure—$24,587———
Free cash flow—-$2.63M———
Investing cash flow—-$24,587———
Financing cash flow$8.16M-$7.00M$11.54M-$1.62M$18.57M
Depreciation & amortization—$2.83M$3.28M$5.60M$6.88M
Stock-based compensation$304,634$197,215$417,230$1.20M$1.31M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.